Hangcheng GBA Youth Entrepreneurship (Employment) Camp: Helping Returning Students Starting Jobs or Own Businesses

SHENZHEN, CHINA, Oct 31, 2020 - (ACN Newswire) - The Greater Bay Area / GBA Youth Entrepreneurship (Employment) Camp, open for only three months, proudly announces success in helping overseas students find jobs and start their own businesses. More than 50 job seekers and entrepreneurs have joined the Camp for consultation and classes, while 16 entrepreneurial teams have settled in. The Camp held activities during this first quarter, talent, entrepreneurship and policy meetings, lectures on intellectual property (IP) and legal ownership, and courses to help prepare graduates and resident teams to solve issues they will encounter as entrepreneurs. At the same time, Hangcheng GBA Youth Entrepreneurship (Employment) Camp has published articles addressing policies, questions and apprehensions, empowering overseas students returnees.


To help returning overseas students find jobs, and provide an entrepreneurial environment free of worries, Hangcheng, Bao'an District, Shenzhen established the Hangcheng GBA Youth Entrepreneurship (Employment) Camp. [10/27/20]


The Coronavirus outbreak of 2020 brought challenges to all countries; an International Labor Organization survey suggested that one-sixth of the world's young people remain unemployed. The pandemic isn't subsiding, and entrepreneurship and employment are tested to their limits. The employment situation for overseas students is even more worrying: these students cannot return to China and can only stay abroad; all the major enterprises have laid-off workers or reduced their salaries, making it difficult for the most competitive international students to find jobs, or face unemployment. The pandemic has impacted the original supply chain and capital chain for entrepreneurs, dealing many entrepreneurial teams fatal blows.

To reverse the social impact of the epidemic, the Chinese government has made employment and entrepreneurship a major task over this and the next few years. Various parts of China have issued favorable policies on employment and entrepreneurship, tried every possible means to stabilize and expand employment, and actively supported the masses' Entrepreneurship and innovation. In terms of talent recruitment, Shenzhen Special Economic Zone has been at the forefront of the country. To help returning overseas students find jobs, and provide an entrepreneurial environment free of worries for returnees, the Hangcheng Sub-district, Bao'an District, Shenzhen, established the Hangcheng GBA Youth Entrepreneurship (Employment) Camp.

Bao'an District of Shenzhen is the heartland of the Guangdong-Hong Kong-Macao Greater Bay Area, close to the airport wharf and Bao'an International Airport. Bao'an is an important place of industry and innovation in Shenzhen and Guangdong Province. Bao'an District was selected eighth of the top 100 districts in China, In 2018; on March 4, 2020, Bao'an District ranked in the National Demonstration Base of New Industrialization by the Ministry of Industry and Information Technology. This is where the Hangcheng GBA Youth Entrepreneurship (Employment) Camp was founded.

Bao'an's unique geographical and economic advantages will likely provide even more help for the entrepreneur. For overseas students, the main causes of employment difficulties are the lag of domestic employment news, maladjustment to the domestic environment, and lack of work experience. To assist with these issues, the Hangcheng GBA Youth Entrepreneurship (Employment) Camp, with it's well established services system, provides the following:

- Help returning overseas students with an academic degree certification, in the form of settlement introductions, subsidy applications, and other guides;
- Resume optimization, interview guidance, career planning, and other help in updating the latest recruitment information in Bao'an District;
- Organizing enterprise introductory activities for overseas students to visit key enterprises in Bao'an, so as to help them better integrate into the domestic environment.
- Professional policy consultants and senior HR to solve overseas students' employment problems.

As for returnee entrepreneurial teams, Hangcheng GBA Youth Entrepreneurship (Employment) Camp will surely become a leading choice to start a business back home. In addition to its Greater Bay Area location, the Hangcheng GBA Youth Entrepreneurship (Employment) Camp can provide 3-6 months of free office space for an entrepreneurial team. The space features a beautiful environment with complete support facilities: Additional to the office area are a reception area, roadshow hall, conference room, multi-function room, and other features. At the same time, it is equipped with a cafe, book bar, gym, and shower room, providing leisure space for entrepreneurs.

Free venues for entrepreneurs are provided in the early stage of entrepreneurship. Lectures on policy, business, finance, taxation, and legal affairs and invite experts to answer questions and doubts for entrepreneurs will be held time to time. Cooperation with investment institutions to provide financial support for entrepreneurs' one-on-one investment in the middle stage of entrepreneurship, and match the appropriate follow-up incubation resources for entrepreneurs when the team matures.

To know more, please send a CV and project introduction to: bella@hexcubes.com

Contact: Eve@hexcubes.com
Telephone: +86 17603014024
Website: https://www.hexcubes.com
Address: Floor 2, Building 2, Baoxing Widsom City,
Qianjin No.2 Road, Baoan District, Shenzhen, China

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/62243/

トヨタ自動車とKDDI、新たな業務資本提携に合意

TOKYO, Oct 30, 2020 - (JCN Newswire) - トヨタ自動車株式会社(本社 : 愛知県豊田市、代表取締役社長 : 豊田 章男、以下「トヨタ」)とKDDI株式会社(本社 : 東京都千代田区、代表取締役社長 : 髙橋 誠、以下「KDDI」)は、両社の提携関係の更なる強化を目的に、本日新たな業務資本提携に合意しましたので、以下のとおりお知らせします。

背景
2000年10月に第二電電株式会社(DDI)、KDD株式会社、日本移動通信株式会社(IDO)の三社合併によりKDDIが発足して以来、トヨタはKDDIの第2位の大株主(2020年9月末時点の持株比率12.95%)として、2002年以降は、トヨタのテレマティクス事業であるG-BOOKサービス等で協業してきました。また、クルマのインターネットへの「つながる化」が進む中、両社は2016年から車載通信機とクラウド間の通信において、高品質で安定した通信をグローバルに確保するために、従来のローミングサービスなどに依存しない、グローバル通信プラットフォームの共同構築を推進するなど、クルマと通信の融合によって安全や快適さを提供する取り組みを加速させてきました。

業務提携の内容
現在両社は、街、家、人、クルマの全てがつながる未来社会の到来に向け、それぞれの中核事業である「移動」と「通信」の枠を超えて新しい取り組みを加速しております。

今回、通信技術およびコネクティッドカー技術の研究開発を推進するとともに、人々の生活を豊かにするサービスの開発や、ビッグデータの活用などによる社会課題解決に取り組んでいきます。具体的には、以下の取り組みを両社で推進していきます。

両社の今後の取り組み
- 4G、5G、6Gなど通信規格が進化する中で、街、家、人、クルマそれぞれの間での最適な通信を可能とする通信プラットフォームの研究開発を共同で実施。
- デバイスからネットワーク、プラットフォーム、サービスまで一元化して管理し、高度な運用を可能とする次世代コネクティッドカー向けの運用管理システムを共同で開発。
- クルマの内外に囚われることなく、人々の生活を豊かにし、安心安全を追求していくサービスおよびサービスプラットフォームを共同で構築。
- 街、家、人、クルマなどのビッグデータを活用した、都市と地方間や各地域のコミュニティにおける社会課題解決を共同で推進。

資本提携の内容
以上の業務提携の合意を背景に、両社が中長期に渡って戦略的な提携を進めるためには、さらなる資本関係の強化が必要との判断に至り、両社は、トヨタを引受先としたKDDI株式18,301,600株(総額約522億円)の第三者割当による自己株式処分(注1)を実施することに合意しました。

これにより、トヨタによるKDDIの持株比率は13.74%となる予定です。株式取得日(払込期日)は2021年1月29日を予定しております。

本リリースの詳細は下記URLをご参照ください。
https://global.toyota/jp/newsroom/corporate/34209580.html

概要:トヨタ自動車株式会社

詳細は http://toyota.jp/ をご覧ください。


Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Valarhash Launches New Service Series for its Mining Hosting Operations

CHENGDU, CHINA, Oct 31, 2020 - (ACN Newswire) - Valarhash, a leader in digital asset services, officially launches a new series of cryptocurrency miner hosting services, now enabling customers with remote online access to the operations of their mining machines. Registered users will have many features such as selecting their mining pool, withdrawing options and even re-selling their mining machine on the platform. Customers can purchase machines from Valarhash or other providers and have them shipped to the Valarhash mining farms.

Valarhash is launching the new service series following an earlier announcement launching miner machine hosting plans. With versatility being of the utmost importance, Valarhash adds the new series of features in order to distinguish itself from its counterparts. The Valarhash mining pool charges a handling fee of 2%, and users are free to assign a designated mining pool for their mining machine based on their needs, offering a customizable experience. This ensures a reliable supply of computing power to consumers which can be viewed in real-time via an app or web management system built by the platform.

Kevin Huang, co-founder of Valarhash, said "given that higher BTC prices would result in a rise in the price of a mining machine, we have decided to allow users to opt out of the hosting services and to re-sell their machines and computing power at any time." Valarhash hosts a large mining community and manages 100,000 mining machines in its facilities, with maintenance available 24/7. In order to respond promptly to glitches and other concerns, on-site operations and repairs will be carried out by Valarhash staff as they occur, without the need for customers to pay fees in advance.

Valarhash, with its large scale operations, is able to standardize procedures and regulate mining costs because of its longstanding partnerships with local power stations. Customers can take advantage of the Valarhash hosting service for an annual fee of $0.046 (KW/H), in comparison to the rates provided on other sites where the annual fee is $0.055 (KW/H) and above. This hosting fee is inclusive of both the operating and maintenance costs of the mining machines.

For information about the new services, please visit our official website to get in touch with a representative.

Website: https://www.valarhash.com
Twitter: https://twitter.com/VaIarhash
Facebook: https://www.facebook.com/Valarhash
Linkedin: https://www.linkedin.com/company/vhash/
Medium: https://medium.com/@Valarhash
Telegram: https://t.me/valarhashx1tmine

About Valarhash
Chengdu-based Valarhash integrates mining machine sales, miner hosting, mining pool and mine construction services. Led by CEO Fiona Lv, Valarhash aims to provide users with transparent and beneficial mining plans using advanced technology, with a lower barrier of entry. Business operations cover hardware research and development, digital asset transactions and 1TMine hash power contract sharing. With a leading position in the hash power market, Valarhash integrates frontier resources with global vision, providing crypto compute service (CCS) and linking physical and digital worlds with blockchain technology. Email: BD@vhash.io.

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/62399/

みんながハッピーになれる業界NO1の楽しいオンラインカジノ「アロハシャーク」がリリース

Fun Entertainment B.V. は、「みんなファミリー」をテーマに掲げた、みんながハッピーになれる業界No1の楽しいカジノ「アロハシャーク」をオープン致しました。

みんながハッピーになれるオンラインカジノ!アロハシャーク
URL: https://www.alohashark.com/ja

アロハシャークは「みんなファミリー」をテーマに掲げた業界No1の『楽しいカジノ』です。

ブラックジャック、バカラ、ポーカー、ルーレットなどのおなじみのテーブルゲームや一攫千金のアメリカンドリームに心踊るスロットやジャックポットの数々。
ゲームが楽しいことはもちろんですが、ユーザーの皆様が安心して楽しんで頂けるためのバックアップ体制を整えることを一番重視しております。

■安心・安全のサポート体制
アロハシャークでは、午後12時から午前12時にライブチャットとメールにて、お客様からのお問い合わせに対応させて頂きます。
迅速且つ親切丁寧なサポートを心がけておりますので、いつでもご連絡ください。

■入出金がわかりやすくて早い!!
「入金が反映されるか・・」「ちゃんと引き出しできるか」
ユーザー様にとって最も大事なのが入出金周りの対応です。入出金方法はとてもシンプルで反映が早く、また視覚的にもとてもわかりやすいのでご安心ください。
勝利金の引き出し速度は業界No1です。

■多彩で豪華なボーナスやイベント数々!!
超豪華な最大1500ドルのウェルカムボーナスや、アンケートにお答えするだけで5ドルがもらえてしまう超シンプルボーナス。さらには、毎週金曜日にライブカジノで遊べる5ドルボーナスも進呈中です(※アンケートボーナスとライブカジノボーナスは入金なしでご利用頂けるスペシャルボーナスとなっております。ライブカジノボーナスは2020年11月末までを予定)。さらにさらに、クリスマス、ニューイヤー、スプリングキャンペーン、そして超豪華景品としてハワイ旅行をプレゼントしてしまう驚きのイベント?!と、様々なイベントを準備しております。
最高に華やかで楽しいオンラインカジノの空間を提供させて頂きます。

■ライセンスに基づき合法的に運営しています
アロハシャークでは、数あるオンラインカジノのライセンスの中でも最も格式が高く審査も厳しいキュラソーライセンスを取得し、第三機関の厳格な監査の元、運営がされております。

■紹介システム(アフィリエイト)も搭載!!
業界最高水準のアフィリエイト報酬レートを設定しております。紹介しやすいように多数のバナー広告やアニメーション広告を準備しております。アフィリエイト報酬はアロハシャークのプレイアカウントへ引き出しが可能となっております。(ecoPayz等のオンラインウォレットへの引き出しも行えるよう準備中)
登録はたったの3分で終了。アロハシャークのホームページよりご確認ください。

現在、グランドキャンペーン期間につき、以下の特別ボーナスを進呈します。
1.業界最大のウェルカムボーナス
2.毎日ログインするだけでもらえるデイリーボーナス
3.アンケートに答えるだけでももらえる特別ボーナス
4.毎週金曜日にはライブカジノで遊べる5ドルボーナス

業界No1の楽しいカジノ「アロハシャーク」で是非お楽しみください。

みんながハッピーになれるオンラインカジノ!アロハシャーク
URL: https://www.alohashark.com/ja

■アロハシャーク運営会社情報

会社名:Fun Entertainment B.V.
会社所在地:Emancipatie Boulevard Dominico F. "Don" Martina 29, Curacao
会社番号:153952
URL: https://www.alohashark.com/ja




Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Avance Clinical Wins MasterControl 2020 Innovation Excellence Award

ADELAIDE, AU, Oct 30, 2020 - (JCN Newswire) - The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.

Avance Clinical made the announcement today at AusBiotech 2020 (28 - 30 October, 2020).
https://www.ausbiotechnc.org/

Avance Clinical CEO Yvonne Lungershausen said the company was very pleased to be awarded such recognition by MasterControl, a leader in the clinical digital management technology.

The MasterControl Clinical Excellence solution streamlines eTMF management and helps clients achieve real-time visibility into critical clinical processes across operational teams - all on one centralized platform. https://www.mastercontrol.com/clinical/

"The award acknowledges our leadership as Australia's biotech CRO and it provides further confidence to our clients that we are serious about delivering quality clinical research services by being nimble and adaptive, and by utilising state-of-the-art systems that are compliant with industry standards, such as MasterControl eQMS," said Yvonne Lungershausen.

"Avance Clinical invests significantly in the industry's leading clinical technologies making it one of the most advanced CROs globally for digital clinical research management and eClinical solutions."

On presenting the Innovation Excellence Award, MasterControl said the award recognises "the power of innovation and celebrates companies who feel the same way we do, who are not afraid to shed the status quo to find their own path and who push boundaries and spearhead important changes within their industries. Companies driven by innovation who truly live and breathe it."

Avance Clinical Director Quality Assurance, Priyanka Chamoli, said:
"Receiving the award from MasterControl is a testament of our commitment to invest in our Quality Management System and to continually improve and strengthen it. This Award recognises and provides visibility to our efforts to push boundaries and adopt this significant change not just for the Quality Assurance department but across-the-board in the organisation."

"MasterControl eQMS enables accurate, streamlined processes for Document Control and Training. Avance Clinical, which is on a significant growth trajectory, requires robust procedures as part of our QMS. MasterControl has allowed our staff to create/review and access our controlled documents in real-time and the automated link between different modules enables timely delivery of training."

Avance Clinical Director Compliance and Training, Lisa Eglinton said:
"MasterControl Training Module provides a robust, user-friendly method for the delivery of role-specific training programs to all staff. The system provides a real-time indication of training status to Trainees and their Line Managers which ensures training compliance across the company."

Avance Clinical is the leading Australian owned CRO that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.

Considering Australia? Contact us about your next study. https://www.avancecro.com/eclinical-solutions/

See Image here http://bit.ly/AvanceClinicalMasterControl
(From left to right) Priyanka Chamoli, Director Quality Assurance, Emma Woolman, Senior Compliance and Training Officer, Yvonne Lungershausen, Avance Clinical's CEO, and Lisa Eglinton, Director Compliance and Training.

About Avance Clinical www.avancecro.com

Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons

Media Contact:
media@avancecro.com
Chris Thompson


Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Gainsky Investmentsのトレーディング・チームは、ミラー・トレーディングを通じてポートフォリオの成長を支援します

ミラー取引とは、トレーダーがエキスパートトレーダーの取引戦略に従ったり、コピーしたりすることを可能にする方法です。このタイプの取引により、新規のトレーダーは予備知識がなくても市場に参入して取引を行うことができます。Gainsky Investmentsでは、深い取引知識がなくてもポートフォリオを成長させることができるよう、ミラー取引を顧客に提供しています。以下では、同社のこのプラットフォーム上で取引を策定し、実施する専門家チームを紹介いたします。

最初の取引チームは、ポール・ギデオン率いるイーグル・トレード・チーム(レッド・チーム)と呼ばれるもので、スリー・イン・ア・ロウ戦略を採用しています。このGainskyトレードチームは、指数移動平均(EMA)、相対ストレングス指数(RSI)、ストキャスティクスオシレーターを使用しています。この戦略は、3つの異なる期間設定(5日と10日)を持つ2つのEMA、1つのデフォルトのRSAと1つのストキャスティクスで構成されています。これらの指標を使用することで、トレーダーはどんな市場の変化にも柔軟に対応できるようになります。

2つ目のトレードチームは、チャールズ・クイントンが率いるフラッシュライト・トレードチーム(イエローチーム)と呼ばれています。2つの有名な指標で構成された "ツーフィンガー"戦略を採用しています。移動平均線(MA)とフラクタルズです。この戦略では、5日と22日の期間設定で2つの単純な移動平均を使用しています。これらのMAを通して、トレーダーは明らかに進行中のトレンドを見て、そこからレバレッジをかけることができるようになりました。

カール・シュミットが率いる第三のトレーディングチームは、テッド・トレード・チーム(ブルーチーム)と呼ばれています。このチームは、フォーティーン戦略を使用しています。この戦略は、デジタル資産のようなボラティリティの高い市場でトレーダーがお金を稼ぐことを可能にする、より長い時間枠で効果的であると考えています。移動平均線で構成されており、期間設定は14日、最大200日となっています。Gainskyチームの中では最も収益性の高い戦略ではありませんが、一貫性があり安全性が高いというメリットがあります。

これらのGainsky Investmentsチームは、どのようなタイプのトレーダーでもFXやクリプトカレンシー市場で利益を上げることを可能にしています。また、これらのチームはトレーダーのポートフォリオを成長させる役割も担っており、トレーダーが獲得した利益を最大化させることができます。

Gainskyについて

Gainskyは、アイビーリーグ出身のロバート・ベンツ氏(CEO)が率いるウェルスマネジメントとトレーディングサービスを提供する企業で、財務管理を専門としています。ベンツ氏はデジタルアセット業界に大きなビジネスチャンスを感じ、2018年に同社を設立しました。ドイツに本社を置きますが、中国をはじめとするアジア地域でのプレゼンスを高めています。

連絡先
ウェイン・ピータース
media@gainsky.com




Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Gainsky Investmentsのトレーディング・チームは、ミラー・トレーディングを通じてポートフォリオの成長を支援します

BERLIN, GERMANY, Oct 30, 2020 - (JCN Newswire) - ミラー取引とは、トレーダーがエキスパートトレーダーの取引戦略に従ったり、コピーしたりすることを可能にする方法です。このタイプの取引により、新規のトレーダーは予備知識がなくても市場に参入して取引を行うことができます。Gainsky Investmentsでは、深い取引知識がなくてもポートフォリオを成長させることができるよう、ミラー取引を顧客に提供しています。以下では、同社のこのプラットフォーム上で取引を策定し、実施する専門家チームを紹介いたします。




最初の取引チームは、ポール・ギデオン率いるイーグル・トレード・チーム(レッド・チーム)と呼ばれるもので、スリー・イン・ア・ロウ戦略を採用しています。このGainskyトレードチームは、指数移動平均(EMA)、相対ストレングス指数(RSI)、ストキャスティクスオシレーターを使用しています。この戦略は、3つの異なる期間設定(5日と10日)を持つ2つのEMA、1つのデフォルトのRSAと1つのストキャスティクスで構成されています。これらの指標を使用することで、トレーダーはどんな市場の変化にも柔軟に対応できるようになります。

2つ目のトレードチームは、チャールズ・クイントンが率いるフラッシュライト・トレードチーム(イエローチーム)と呼ばれています。2つの有名な指標で構成された "ツーフィンガー"戦略を採用しています。移動平均線(MA)とフラクタルズです。この戦略では、5日と22日の期間設定で2つの単純な移動平均を使用しています。これらのMAを通して、トレーダーは明らかに進行中のトレンドを見て、そこからレバレッジをかけることができるようになりました。

カール・シュミットが率いる第三のトレーディングチームは、テッド・トレード・チーム(ブルーチーム)と呼ばれています。このチームは、フォーティーン戦略を使用しています。この戦略は、デジタル資産のようなボラティリティの高い市場でトレーダーがお金を稼ぐことを可能にする、より長い時間枠で効果的であると考えています。移動平均線で構成されており、期間設定は14日、最大200日となっています。Gainskyチームの中では最も収益性の高い戦略ではありませんが、一貫性があり安全性が高いというメリットがあります。

これらのGainsky Investmentsチームは、どのようなタイプのトレーダーでもFXやクリプトカレンシー市場で利益を上げることを可能にしています。また、これらのチームはトレーダーのポートフォリオを成長させる役割も担っており、トレーダーが獲得した利益を最大化させることができます。

Gainskyについて

Gainskyは、アイビーリーグ出身のロバート・ベンツ氏(CEO)が率いるウェルスマネジメントとトレーディングサービスを提供する企業で、財務管理を専門としています。ベンツ氏はデジタルアセット業界に大きなビジネスチャンスを感じ、2018年に同社を設立しました。ドイツに本社を置きますが、中国をはじめとするアジア地域でのプレゼンスを高めています。

連絡先
ウェイン・ピータース
media@gainsky.com


Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

富士通、「テレワーク先駆者百選」の最高賞「総務大臣賞」を初めて受賞

TOKYO, Oct 30, 2020 - (JCN Newswire) - 当社はこのたび、総務省が主催する「テレワーク先駆者百選」において、最高位となる「総務大臣賞」を初めて受賞しました。

新型コロナウイルスの感染拡大を受けた日本政府による緊急事態宣言下での高いテレワーク実施率や、ニューノーマル(新常態)における新しい働き方のコンセプト「Work Life Shift」のもとで推進しているテレワーク勤務を基本とした様々な取り組みが高く評価されたものです。

当社は今後も、「パーパス」(注1)の実現に向けた最適な働き方を追求していくとともに、社内実践した新たな働き方をお客様にリファレンスとして提供することで、お客様のDXの実現にも貢献していきます。

「テレワーク先駆者百選 総務大臣賞」について
総務省は、2015年度から、テレワークの普及促進を目的として、テレワークの導入・活用を進めている企業・団体を「テレワーク先駆者」とし、その中でも十分な実績を持つ企業・団体を「テレワーク先駆者百選」として公表しています。

2016年度からは、「テレワーク先駆者百選」に選定された企業などの中から、他社が模範とすべき優れた取り組みを行っている企業などに対し、最高位の賞として「総務大臣賞」を授与しています。

受賞理由について
当社は、新型コロナウイルスの急速な感染拡大によって発出された日本政府による緊急事態宣言を受け、国内グループ従業員(注2)に対する原則テレワーク勤務を実施し、約90%という高い実施率を達成しました。

また、緊急事態宣言の解除後も、ニューノーマルにおける新しい働き方のコンセプト「Work Life Shift」を定め、約8万人の国内グループ従業員の基本となる勤務形態をテレワークとし、実施率約80%を継続しています。さらに、テレワークと出張を組み合わせることで、単身赴任者の自宅勤務への切り替えなども推進してきました。

このような積極的なテレワークへの取り組みが高く評価されました。

「Work Life Shift」の概要
当社は、新型コロナウイルスの感染拡大によって生じたニューノーマルにおいて、DX(デジタルトランスフォーメーション)企業への変革をさらに加速し、従業員がこれまで以上に高い生産性を発揮し、イノベーションを創出し続けられる新しい働き方として「Work Life Shift」を推進します。

「Work Life Shift」は、「働く」ということだけでなく、「仕事」と「生活」をトータルにシフトし、Well-beingを実現するコンセプトです。本コンセプトのもと、固定的なオフィスに出勤する従来の通勤の概念を変え、多様な人材が高い自律性と相互の信頼に基づき、場所や時間にとらわれることなく、お客様への提供価値の創造と自らの変革に継続的に取り組むことができる働き方を実現するため、人事制度とオフィス環境整備の両面から様々な施策を推進しています。

本リリースの詳細は下記をご参照ください。
https://pr.fujitsu.com/jp/news/2020/10/30.html

概要: 富士通株式会社

詳細は http://jp.fujitsu.com/ をご覧ください。


Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

三菱自、クロスオーバーSUV 新型『エクリプス クロス』が「2020年度グッドデザイン賞」を受賞

TOKYO, Oct 30, 2020 - (JCN Newswire) - 三菱自動車工業株式会社(本社:東京都港区、代表執行役CEO:加藤 隆雄、以下三菱自動車)は、本年12月に発売を予定しているクロスオーバーSUV 新型『エクリプス クロス』が、公益財団法人日本デザイン振興会の主催する「2020年度グッドデザイン賞*1」を受賞したことを発表しました。

この度の受賞では、PHEV(プラグインハイブリッドEV)システムの採用による走行性能や環境性能の向上、都会的で上質なフォルムへの進化が高く評価されました。

【新型『エクリプス クロス』の特長】
新型『エクリプス クロス』は三菱自動車らしさを追求したクロスオーバーSUVとして、(1)行動意欲を掻き立てる個性的なデザイン、(2)モータードライブを心ゆくまで楽しめるPHEV、(3)四輪制御技術による安心して楽しめるドライビングフィール、を特長としています。

従来型からフロントとリヤのデザインを⼀新し、上質感を高めながらいっそう流麗で洗練されたフォルムとしたほか、荷室容量を拡大してSUV としての使い勝手をさらに高めました。また、ツインモーター4WD 方式のPHEV モデルを新たに設定。モータードライブならではの力強さと静かで滑らかな加速、車両運動統合制御システムS-AWC*2がもたらす思い通りの操縦性、軽快感と安心感で新型『エクリプス クロス』の走りの魅力を高めています。

【審査員評価コメント】
「ガソリンまたはディーゼルエンジンを搭載していた従来型『エクリプス クロス』に、アウトランダーで実績のある充電機能を備えたプラグインハイブリッドEVシステムを導入し、走行性と環境性を向上させた。電動化コンポーネントを収納するために全長を140mm延長しているが、特にその内105mm延長となるリヤ部のデザインを工夫することで、従来型よりエレガントなフォルムにまとまっている。都会の上質な空間に似合うクーペSUVがさらに進化したといえよう。」

新型『エクリプス クロス』のスペシャルサイトはこちら
https://www.mitsubishi-motors.co.jp/lineup/eclipse-cross/special/index.html

本リリースの詳細は下記をご参照ください。
https://www.mitsubishi-motors.com/jp/newsrelease/2020/detail5481.html

概要:三菱自動車工業株式会社

三菱自動車の企業コミュニケーションワード「Drive@earth」
地球を走る。地球と生きる。三菱自動車。

人とクルマ、社会とクルマ、地球とクルマの新しい時代を拓くために。いま、三菱自動車は挑戦を始めています。走行中のCO2排出ゼロ。地球温暖化防止に貢献する新世代電気自動車、i MiEV(アイミーブ)の世界投入。軽自動車で培った技術を存分に活用、燃費性能にすぐれたグローバル・スモールの提案。世界の環境基準をクリアしながら、走りの楽しさにあふれた三菱ならではの小型SUVの開発。さらに、新ディーゼルエンジンによるラリー参戦を通じて、走りと環境を両立する、新次元のクルマづくりを追求してゆきます。

私たちは信じています。私たちのクルマへの熱い想いと技術が、新しいクルマの価値をつくることを。ドライブ・アット・アース。走る歓びが永遠であるように。クルマが地球と共生できるように。

詳細はこちらからご覧ください。 www.mitsubishi-motors.co.jp


Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

三菱自、離島における災害時の電動車派遣にMMCレンタカーを活用へ

TOKYO, Oct 30, 2020 - (JCN Newswire) - 三菱自動車工業株式会社(本社:東京都港区、代表執行役CEO:加藤 隆雄、以下三菱自動車)は29日、災害時に電動車を速やかに被災地・避難所へ提供できる体制づくりを全国で目指す「DENDOコミュニティサポートプログラム」の一環として、鹿児島県奄美大島の瀬戸内町(鎌田かまだ 愛人なるひと町長)など※1と災害時協力協定(以下災害協定)を締結しました。離島の自治体との災害協定締結は初めて。また、従来は当社系列販売店の保有車を貸し出す体制でしたが、今回より、離島においては当社製レンタカーも活用できる体制とし、災害時の速やかな支援体制づくりに協力いたします。

災害協定の狙いは、災害発生時に改めて自治体と必要事項を確認する時間的ロスをなくし、給電等に活用できるプラグインハイブリッド電気自動車『アウトランダーPHEV』などの電動車を速やかに被災地・避難所へ届けることです。離島においては、地理的な条件から災害時に自治体へ貸与できる電動車が不足すると想定し、当社100%子会社のMMCダイヤモンドファイナンス株式会社(代表取締役社長:服部 俊彦)が全国で展開する「MMCレンタカー」として登録している電動車を、地元のレンタカー会社の協力を得ながら貸し出せる体制をつくることとなりました。

鹿児島県内の協定締結は28日の鹿児島市に続いて2例目、全国では83例目となりました。当社執行役員の若林 陽介は29日の締結式で「豊かな自然遺産を守りながら地元の産業振興を目指している瀬戸内町の安心・安全な街づくりに貢献できると思います。瀬戸内町および地元企業のご協力に感謝申し上げます」と述べました。

当社は今後も、全国の自治体がそれぞれ抱える事情に寄り添いながら、電動車を活用した災害時支援の在り方を検討し、実行してまいります。

本リリースの詳細は下記をご参照ください。
https://www.mitsubishi-motors.com/jp/newsrelease/2020/detail5482.html

概要:三菱自動車工業株式会社

三菱自動車の企業コミュニケーションワード「Drive@earth」
地球を走る。地球と生きる。三菱自動車。

人とクルマ、社会とクルマ、地球とクルマの新しい時代を拓くために。いま、三菱自動車は挑戦を始めています。走行中のCO2排出ゼロ。地球温暖化防止に貢献する新世代電気自動車、i MiEV(アイミーブ)の世界投入。軽自動車で培った技術を存分に活用、燃費性能にすぐれたグローバル・スモールの提案。世界の環境基準をクリアしながら、走りの楽しさにあふれた三菱ならではの小型SUVの開発。さらに、新ディーゼルエンジンによるラリー参戦を通じて、走りと環境を両立する、新次元のクルマづくりを追求してゆきます。

私たちは信じています。私たちのクルマへの熱い想いと技術が、新しいクルマの価値をつくることを。ドライブ・アット・アース。走る歓びが永遠であるように。クルマが地球と共生できるように。

詳細はこちらからご覧ください。 www.mitsubishi-motors.co.jp


Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Agilex Biolabs Client Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program

ADELAIDE, AU, Oct 30, 2020 - (JCN Newswire) - Agilex Biolabs, Australia's most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company's lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.

San Francisco-based Shasqi said in the announcement:

First Patients Dosed in Phase 1 Clinical Study of SQ3370 for Advanced Solid Tumor Malignancies

Shasqi is First Y-Combinator Biotech Company to Reach First-in-Human Clinical Studies

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPACtm) Platform, announced today the first-ever application of click chemistry in humans, with the launch of the Company's lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.

The first two patients have been dosed in Shasqi's Phase 1 clinical study of SQ3370 for the treatment of advanced solid tumors. SQ3370 is a novel investigational product that activates a non-toxic protodrug into a powerful chemotherapy agent, doxorubicin, precisely at a pre-injected tumor. SQ3370 is designed to allow substantially higher drug doses to be given to the patient, increasing tumor destruction while minimizing toxicity in the rest of the body.

"Shasqi is founded on the belief that one day we will be able to beat cancer without poisoning our bodies. We are excited to reach this milestone with our CAPAC Platform and the launch of Shasqi's first clinical program," said Jose M. Mejia Oneto, M.D., Ph.D., Founder and CEO of Shasqi.

The CAPAC Platform is a new therapeutic modality based on click chemistry, which leverages biocompatible chemical reactions, to activate protodrugs at a selected tumor that has been pre-injected with a biopolymer. The CAPAC platform is agnostic to tumor characteristics that can vary from patient to patient, such as biomarker expression and enzymatic activity, rendering it applicable to a broad array of tumor types. Additionally, the CAPAC Platform is highly modular and can be applied to a wide variety of cancer therapeutics in addition to doxorubicin.

"Doxorubicin has been proven effective for dozens of cancers, but severe side effects limit its use. Guiding it directly to the tumor while avoiding damage to the rest of the body may allow us to use doxorubicin and potentially many other drugs in a completely new and effective way for patients," commented Wayne Saville, M.D., Chief Medical Officer of Shasqi. "Shasqi has taken a novel concept through a rigorous preclinical regulatory path all the way to treating patients in near-record time."

"Shasqi was Y Combinator's first therapeutic biotechnology investment and now the first of our life sciences companies to reach clinical development," said Jared Friedman, Partner, Y Combinator. "We are extremely impressed by the team's rapid advancement and capital-efficient execution. SQ3370 and CAPAC are not just a standard new small molecule, but rather a broad and powerful new platform leveraging state of the art science and materials to transform the treatment of cancer."

SQ3370-001 (NCT04106492) is a multicenter, first-in-human, dose-escalation, Phase 1 clinical trial evaluating the safety and tolerability, pharmacokinetics, immune effects, and preliminary anti-tumor efficacy of SQ3370 in patients with locally advanced or metastatic solid tumor malignancies ineligible for standard-of-care therapy. The study is being conducted in the United States and Australia at multiple cancer centers, including MD Anderson Cancer Center and Stanford University. The study is expected to be completed in 2021. More information about the trial is available at: https://clinicaltrials.gov/ct2/show/NCT04106492.

See the announcement here. https://tinyurl.com/y2splohj

Agilex Biolabs is known internationally for its continued investment in the latest technology, and for attracting some of the leading scientists from Australia and around the world.

Agilex Biolabs, the only FDA-inspected lab of its type in the region, also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.

Agilex Biolabs' world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.

The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the New Labs Walkthrough Video Here https://www.agilexbiolabs.com/new-labs-video

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs has more than 90 staff including 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs companies from US, Europe and APAC.

Please Book a Briefing with us before you start your next clinical trial. https://calendly.com/agilexbiolabs/15min

About Agilex Biolabs https://www.agilexbiolabs.com/

Agilex Biolabs, Australia's leading bioanalytical laboratory, has more than 20 years' experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world's most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

Agilex Biolabs Media Contact:
Media@AgilexBiolabs.com
Kate Newton

Shasqi media contact:
David Rosen, Argot Partners
media@shasqi.com
+1 (212) 600-1902


Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

The Edvantage Group (0382.HK)'s Edvantage Institute (Singapore) Benefits from Hong Kong-Singapore Travel Bubble

HONG KONG, Oct 30, 2020 - (ACN Newswire) - Edvantage Group Holdings Limited ("Edvantage Group" or the "Company", together with its subsidiaries, the "Group"; stock code: 0382.HK), the largest private higher education group in the Greater Bay Area is pleased to announce that its Edvantage Institute (Singapore) ('EIS') had commenced operation as scheduled. EIS, formerly a language school, brings quality and renowned tutors in language education together, and its online English programmes taught by Singaporean native tutors are now wildly popular, which proves the COVID-19 pandemic has not hindered Chinese and Singaporean students' learning ambitions. As Hong Kong and Singapore have already reached an in-principle agreement to establish a bilateral Travel Bubble, overseas studies and experience are now awaiting students.


Left: Singaporean tutors teaching online English courses for students in China; Middle: Teachers and students merrily gathering at EIS; Right: Renowned tutors lecturing at EIS


Campus Situated at Premium Location, International Financial Hub Strengthens Global Horizon
NYU Language School, the predecessor of EIS, has over a 20-year history with a well-developed English teaching scheme as well as academic standards. The campus is situated at the centre of Singapore and possesses a premium geographical location, convenient transport and optimal daily facilities. Moreover, it is surrounded by various tertiary institutes, for example, Singapore Management University and Monash University.

Currently, EIS offers the Group's students with Global Immersion Programmes (GIP) and overseas lectures of various professions, which broaden their horizon and experience as well as help them learn foreign folklore and advanced ideas. Meanwhile, such programmes help students practise their linguistic skills, expand their knowledge and enhance their personal integrated skills, laying a solid foundation for their future study or career overseas as compound talents equipped with globalised vision. At the current stage, EIS provides various courses online and offline for students from Singapore, China and other countries. Such courses have high demand under the pandemic and gain enormous popularity among students.

Fintech Hub Joins Talents from 2 Regions and Offers Students Comprehensive Opportunities
Singapore is one of the world's largest ports and a critical international financial centre. In recent years, Singapore has been dedicated to growing into the largest fintech hub across the world. Singapore Fintech Festival, organised by Monetary Authority of Singapore and known as a top fintech event, has been held for 3 consecutive years, mainly providing a decent platform to demonstrate fruits of the world's latest fintech development. With Singapore's devotion to developing financial and fintech industries, EIS provides programmes in such professions to nurture talents in business, IT, finance, fintech and other related fields. These expectedly sought-after programmes create an advantageous learning platform for students' future internships, continuous education, career and even entrepreneurship.

Singapore Travel Bubble Helps Edvantage's Students Kick off Study Tours and Exchanges
On 19 October 2020, Ministry of Health and Immigration & Checkpoints Authority of Singapore jointly announced to officially resume visa approvals for foreigners. Whilst COVID-19 is still storming other countries, Singapore first managed to control the spread of virus. It becomes the first state with released quarantine restrictions on entering for Hong Kong travellers and will gradually open to more countries or regions, aiming to attract more students to travel, study and experience there. The initiation of Singapore's travel bubble enables students of the Group to kick off study tours and exchanges, consolidating the Group's principle of international education.

About Edvantage Institute (Singapore)
Established in 1991, Edvantage Institute (Singapore) (EIS) has attained the authoritative EduTrust certification from the Ministry of Education, Singapore and is qualified to offer internationally-recognised courses and accept local and overseas students in Singapore. Its predecessor, NYU Language School, has a history of more than 20 years and has developed a sophisticated English teaching scheme as well as academic standards. The campus is situated at the centre of Singapore and possesses a premium geographical location, convenient transport and optimal daily facilities. EIS brings quality and renowned tutors in language education together, and it meets high standards in campus management, academic education, students welfare, backup and financial sustainability. It focuses on professional training in fields including language programmes, education, business and entrepreneurship, mainly providing various diploma and language training programmes. Every aspect, ranging from research to education, completely demonstrates its outstanding students, advanced facilities, globalised vision and cultural diversity.

About Edvantage Group Holdings Limited
Edvantage Group Holdings Limited ("Edvantage Group" or the "Group", stock code: 0382.HK) is the largest private higher education group in the Greater Bay Area and an early mover in education sector in pursuing international expansion. The total number of student enrolments of the Group were 35,444 and the Group owns 5 schools in both China and overseas as of 31 May 2020.

In China, the Group currently operates 2 private higher education institutions in Guangdong Province, namely undergraduate colleges Huashang College Guangdong University of Finance and Economics and Guangzhou Huashang Vocational College, featuring business courses (such as accounting, finance, economics and business English) as the strategic curriculum; In overseas, the Group operates a private vocational education institution named Global Business College of Australia ("GBCA") authorised by Australian Skills Quality Authority (ASQA) in Australia, offering vocational education courses and non-formal short-term courses. GBCA is the first Chinese international education institution approved by the Australian government. In December 2019, the Group has also acquired a private vocational education institution in Singapore, that is, Edvantage Institute (Singapore) ("EIS") (formerly known as NYU Language School), which has been accredited as EduTrust by the Education Department of Singapore. It is qualified to offer internationally-recognised courses and accept local and overseas students in Singapore. Moreover, the Group established a higher education institution Edvantage Institute Australia ("EIA"), which is granted by the Tertiary Education Quality and Standards Agency (TEQSA) in the first quarter of year 2020, and qualified to accept students, offer and award undergraduate and master's degrees. It is expected to start student's recruitment in November 2020.

This press release is issued by Porda Havas International Finance Communications Group for and on behalf of Edvantage Group Holdings Limited For further information, please contact:

Porda Havas International Finance Communications Group
Mr. Bunny Lee +852 3150 6707 bunny.lee@pordahavas.com
Ms. Angela Shi +852 3150 6778 angela.shi@pordahavas.com
Ms. Sarah Liang +852 3150 6765 sarah.liang@pordahavas.com



Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/62380/

Wintermar Offshore (WINS:JK) Reports 9M2020 Results

JAKARTA, Oct 30, 2020 - (ACN Newswire) - Wintermar Offshore Marine (WINS:JK) has announced results for 9M2020. Wintermar's Owned Vessel revenue for 9M2020 was 17% lower YOY at US$24.6 million and there was a slight improvement on a quarterly basis in 3Q2020 compared to 2Q2020.

--Owned Vessel Division

For the 9M2020 period, Owned Vessel Division recorded a gross loss of US$2.8 million, largely due to cancellations and postponement of contracts caused by the pandemic. Cost efficiency measures and a streamlining of the fleet undertaken since last year led to a 14% YOY decline in Owned Vessel direct expenses, which helped mitigate some of the losses.

On a quarterly basis, revenue for 3Q2020 was slightly improved as compared to 2Q2020 while direct expenses fell.

Measures taken to improve cost efficiency resulted in a 14% reduction in direct expenses for Owned Vessels. Fuel costs dropped sharply by 71% YOY while depreciation fell by 14% YOY due to the sale of 4 vessels in the period 1 January 2020 until 30 September 2020. However, due to the cost of extra precautions taken to ensure the health and safety of crew and clients crewing costs were only 3% lower YOY for 9M2020.

--Chartering and Other Services

Chartering was also negatively affected, contributing US$0.4 million to gross profit as compared to US$1 million in 9M2019. Other Services experienced a similar decline and contributed US$0.3 million to gross profit for 9M2020.

--Indirect Expenses and Operating Loss

Overall, indirect expenses were 15% lower YOY, totaling US$4.5 million for 9M2020. The biggest contributor to these savings was a 15% YOY decline in staff salaries. This was due to lower headcount as well as a voluntary salary reduction supported by all levels of management and staff to mitigate the impact of the pandemic. Marketing and travelling expenses fell YOY by 74% and 43% respectively while lower depreciation also contributed to the cost reduction for 9M2020 compared to 9M2019.

The Operating Loss was 17% YOY higher at US$6.5 million for 9M2020.

--Other Income, Expenses and Net Attributable profit

Interest expenses fell by 27% YOY to US$2.5 million, largely due to lower debt as the Company paid off US$5.7 million of bank loans over the past 9 months. Vessel sale proceeds of US$4,9 million added US$1.2 million to other income, while share of associate companies' losses widened to US$0.4 million from US$0.02 million.

For the nine months ending 30 September 2020, the net loss attributable to shareholders totalled US$7.4 million compared to US$5.7 million in 9M2019.

EBITDA for 9M2020 was US$9 million, compared to US$12.5 million booked in 9M2019.

--Oil & Gas Industry

Activity was slow during 3Q2020, as the world continued to grapple with measures to control the COVID-19 pandemic. In South East Asia, charter rates have been stagnant and are unlikely to drop much further as they are barely covering cash costs. However, leading indicators for oil and gas are turning more positive.

In its October report, the International Energy Agency (IEA) projected that world demand for oil would return to 96.1 million bpd by Q42020 compared to an average of 100.1 million bpd for 2019. This represents a sharp recovery from 2Q2020 where global oil demand fell to the lowest point at 83 million bpd. On the supply side, oil and gas production has been hit hard as many Exploration and Production companies have cut back on investments due to financial pressures. OPEC+ has shown high compliance in maintaining lower production. If IEA projections are achieved, excess oil inventories may be drawn down by end of 2020, which is potentially good news for oil price stability and strength in 2021.

A recent study by Rystad Energy has concluded that deepwater drilling costs have fallen to US$50/barrel, lower than US shale production costs. Should oil prices recover, there are several potential offshore projects in SE Asia which could provide increased gas supply.

SKK MIGAS, Indonesia's regulator for the upstream oil and gas sector, has just reiterated in October 2020 their plans to boost oil and gas production to achieve their target of 1 million bpd by 2030 from 746,000 bpd in 2020. Since Indonesia has several discovered but undeveloped fields, this would actually be an achievable goal if the government is able to deliver on their plans for enhanced oil recovery and exploration.

--Strategy and Outlook

As countries have started to ease their COVID-19 restrictions on travel and business activities, there has been a gradual but steady recovery in oil and gas demand. China, which was early to emerge from lockdown, has shown a sharp recovery in economic growth.

The economic slump and spike in unemployment worldwide is being addressed through stimulus packages proposed by governments around the world. The threat of a resurgence of the virus seems to be handled with more localized lockdown measures to limit the harsh economic effects of COVID-19 "lockdown" restrictions. All this points to a gradual recovery of demand for oil in the coming year.

Although 2020 results will continue to be plagued by the pandemic's effect on reducing oil demand, there has started to be more tendering activity in 4Q2020 which is indicative of better times in 2021.

Rystad Energy research is projecting growth in South East Asian gas production. Wintermar has been building up a presence in Malaysia, Brunei and Myanmar for the past few years, as we position the Company to be a major player in Asia.

Contracts on hand as at end September 2020 amount to US$70 million.
Contact:
Ms. Pek Swan Layanto, CFA Investor Relations PT Wintermar Offshore Marine Tbk Tel: +62-21 530 5201 Ext 401 Email: investor_relations@wintermar.com


Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/62379/

Avance Clinical Wins MasterControl 2020 Innovation Excellence Award

ADELAIDE, AU, Oct 30, 2020 - (ACN Newswire) - The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical today accepted the MasterControl 2020 Innovation Excellence Award in a virtual ceremony.


L-R: Priyanka Chamoli, Director Quality Assurance, Emma Woolman, Senior Compliance and Training Officer, Yvonne Lungershausen, Avance Clinical's CEO, and Lisa Eglinton, Director Compliance and Training.


Avance Clinical made the announcement today at AusBiotech 2020 (28 - 30 October, 2020).
https://www.ausbiotechnc.org/

Avance Clinical CEO Yvonne Lungershausen said the company was very pleased to be awarded such recognition by MasterControl, a leader in the clinical digital management technology.

The MasterControl Clinical Excellence solution streamlines eTMF management and helps clients achieve real-time visibility into critical clinical processes across operational teams - all on one centralized platform. https://www.mastercontrol.com/clinical/

"The award acknowledges our leadership as Australia's biotech CRO and it provides further confidence to our clients that we are serious about delivering quality clinical research services by being nimble and adaptive, and by utilising state-of-the-art systems that are compliant with industry standards, such as MasterControl eQMS," said Yvonne Lungershausen.

"Avance Clinical invests significantly in the industry's leading clinical technologies making it one of the most advanced CROs globally for digital clinical research management and eClinical solutions."

On presenting the Innovation Excellence Award, MasterControl said the award recognises "the power of innovation and celebrates companies who feel the same way we do, who are not afraid to shed the status quo to find their own path and who push boundaries and spearhead important changes within their industries. Companies driven by innovation who truly live and breathe it."

Avance Clinical Director Quality Assurance, Priyanka Chamoli, said:
"Receiving the award from MasterControl is a testament of our commitment to invest in our Quality Management System and to continually improve and strengthen it. This Award recognises and provides visibility to our efforts to push boundaries and adopt this significant change not just for the Quality Assurance department but across-the-board in the organisation."

"MasterControl eQMS enables accurate, streamlined processes for Document Control and Training. Avance Clinical, which is on a significant growth trajectory, requires robust procedures as part of our QMS. MasterControl has allowed our staff to create/review and access our controlled documents in real-time and the automated link between different modules enables timely delivery of training."

Avance Clinical Director Compliance and Training, Lisa Eglinton said:
"MasterControl Training Module provides a robust, user-friendly method for the delivery of role-specific training programs to all staff. The system provides a real-time indication of training status to Trainees and their Line Managers which ensures training compliance across the company."

Avance Clinical is the leading Australian owned CRO that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.

Considering Australia? Contact us about your next study. https://www.avancecro.com/eclinical-solutions/

See Image here http://bit.ly/AvanceClinicalMasterControl
(From left to right) Priyanka Chamoli, Director Quality Assurance, Emma Woolman, Senior Compliance and Training Officer, Yvonne Lungershausen, Avance Clinical's CEO, and Lisa Eglinton, Director Compliance and Training.

About Avance Clinical www.avancecro.com

Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team.
The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons

Media Contact:
media@avancecro.com
Chris Thompson

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/62361/

Agilex Biolabs Client Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program

ADELAIDE, AU, Oct 30, 2020 - (ACN Newswire) - Agilex Biolabs, Australia's most advanced FDA-inspected specialist bioanalytical laboratory for clinical trials, congratulates client company Shasqi on the announcement of the first-ever application of click chemistry in humans, with the launch of the Company's lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.

San Francisco-based Shasqi said in the announcement:

First Patients Dosed in Phase 1 Clinical Study of SQ3370 for Advanced Solid Tumor Malignancies

Shasqi is First Y-Combinator Biotech Company to Reach First-in-Human Clinical Studies

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPACtm) Platform, announced today the first-ever application of click chemistry in humans, with the launch of the Company's lead clinical candidate, SQ3370. Shasqi is the first Y Combinator-backed biotech company to reach clinical development.

The first two patients have been dosed in Shasqi's Phase 1 clinical study of SQ3370 for the treatment of advanced solid tumors. SQ3370 is a novel investigational product that activates a non-toxic protodrug into a powerful chemotherapy agent, doxorubicin, precisely at a pre-injected tumor. SQ3370 is designed to allow substantially higher drug doses to be given to the patient, increasing tumor destruction while minimizing toxicity in the rest of the body.

"Shasqi is founded on the belief that one day we will be able to beat cancer without poisoning our bodies. We are excited to reach this milestone with our CAPAC Platform and the launch of Shasqi's first clinical program," said Jose M. Mejia Oneto, M.D., Ph.D., Founder and CEO of Shasqi.

The CAPAC Platform is a new therapeutic modality based on click chemistry, which leverages biocompatible chemical reactions, to activate protodrugs at a selected tumor that has been pre-injected with a biopolymer. The CAPAC platform is agnostic to tumor characteristics that can vary from patient to patient, such as biomarker expression and enzymatic activity, rendering it applicable to a broad array of tumor types. Additionally, the CAPAC Platform is highly modular and can be applied to a wide variety of cancer therapeutics in addition to doxorubicin.

"Doxorubicin has been proven effective for dozens of cancers, but severe side effects limit its use. Guiding it directly to the tumor while avoiding damage to the rest of the body may allow us to use doxorubicin and potentially many other drugs in a completely new and effective way for patients," commented Wayne Saville, M.D., Chief Medical Officer of Shasqi. "Shasqi has taken a novel concept through a rigorous preclinical regulatory path all the way to treating patients in near-record time."

"Shasqi was Y Combinator's first therapeutic biotechnology investment and now the first of our life sciences companies to reach clinical development," said Jared Friedman, Partner, Y Combinator. "We are extremely impressed by the team's rapid advancement and capital-efficient execution. SQ3370 and CAPAC are not just a standard new small molecule, but rather a broad and powerful new platform leveraging state of the art science and materials to transform the treatment of cancer."

SQ3370-001 (NCT04106492) is a multicenter, first-in-human, dose-escalation, Phase 1 clinical trial evaluating the safety and tolerability, pharmacokinetics, immune effects, and preliminary anti-tumor efficacy of SQ3370 in patients with locally advanced or metastatic solid tumor malignancies ineligible for standard-of-care therapy. The study is being conducted in the United States and Australia at multiple cancer centers, including MD Anderson Cancer Center and Stanford University. The study is expected to be completed in 2021. More information about the trial is available at: https://clinicaltrials.gov/ct2/show/NCT04106492.

See the announcement here. https://tinyurl.com/y2splohj

Agilex Biolabs is known internationally for its continued investment in the latest technology, and for attracting some of the leading scientists from Australia and around the world.

Agilex Biolabs, the only FDA-inspected lab of its type in the region, also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.

Agilex Biolabs' world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.

The company has recently expanded its labs by more than 30% to accommodate biotech demand from APAC and the USA. Watch the New Labs Walkthrough Video Here https://www.agilexbiolabs.com/new-labs-video

Agilex Biolabs specialises in bioanalysis of small molecules and biologics for PK, immunogenicity, biomarkers and immunological pharmacodynamics assessments utilising LC-MS/MS, immunoassay (Mesoscale, Gurolab, Luminex) and flow cytometry (BD FACSymphony A3, 20 colour cell analyser).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs has more than 90 staff including 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year they will analyse more than 60,000 samples for pharma/biotechs companies from US, Europe and APAC.

Please Book a Briefing with us before you start your next clinical trial.

About Agilex Biolabs https://www.agilexbiolabs.com/

Agilex Biolabs, Australia's leading bioanalytical laboratory, has more than 20 years' experience in performing regulated bioanalysis, including quality method development, method validation and sample analysis services. We have successfully supported hundreds of preclinical and clinical trials around the world where customers choose Australia for the streamlined regulatory process and access to the world's most attractive R&D rebate of more than 40% on clinical trial work conducted in Australia.

We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

Agilex Biolabs Media Contact:
Media@AgilexBiolabs.com
Kate Newton

Shasqi media contact:
David Rosen, Argot Partners
media@shasqi.com
+1 (212) 600-1902

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/62341/

Raffles Announces 2020 Fiscal Year-End Financial Results

Vancouver, BC, Oct 30, 2020 - (JCN Newswire) - Raffles Financial Group Limited (CSE: RICH) (FSE: 4VO) (OTC: RAFFF) ("Raffles" or "the Company") today announces its financial results for the fiscal year ended June 30, 2020, highlighted by revenue of $8,866,672 and adjusted comprehensive income before other items and income tax expenses of $12,220,573. All amounts expressed are in Singapore dollars.

2020 Financial Highlights:

- Total Revenue of $8,866,672 (2019: $11,533,334)
- Adjusted comprehensive income before other items and income tax expenses3 of $12,220,573 (2019: $10,750,652)
- Cash Flow from operations of $7,044,654 (2019: $11,002,734)
- The Company generated cash inflow from financing activities of $20,296,000 (2019: cash outflow of $8,900,000) related to the completion of a private placement for gross proceeds of $20,296,000.

Comparative Summary of Key Financial Metrics for 2019 and 2020

2020 - 2019
Revenue $8,866,672 $11,533,334
Unrealized gain on investments $4,748,139 -
Operating expenses(*1) $1,565,443 $782,682
Listing expenses for RTO(*2) $6,052,280 -
Adjusted comprehensive income before other items and income tax expenses(*3) $12,220,573 $10,750,652
Net Income (Loss) ($425,229) $9,560,301

(*1) Operating expenses do not include interest, taxes, depreciation (including impairment of intangible assets) and amortization, and other non-recurring Items and non-cash accounting expenses.
(*2) Listing expense relates to the RTO in the amount of $6,052,280, which comprised of a non-cash acquisition consideration of $5,479,920 recognised under IFRS 3 in accounting for the reverse take over transaction ("RTO").
(*3) Adjusted comprehensive income before other items and income tax expenses equals income before other items and income tax expenses plus other comprehensive income includes Foreign currency translation and unrealized gain on investments.

Review of 2020

The Company's sole operating subsidiary, Raffles Financial Private Limited ("RFP"), first appeared in the second quarter of the calendar year 2020, marking the beginning of the Company tapping into the corporate finance advisory segment exclusively. From a financial standpoint, the Company was able to exceed its revenue and earning objectives for the year. From an operational standpoint, the Company disposed its old business and continued to make inroads into the Asia financial market through its services provided by RFP. The highly customisable service provided to its small to medium clients, coupled with its unique professional and low-cost service, are value-propositions that continue to resonate with and account for its adoption rate among industry players.

Outlook for 2021

- Significant opportunities for Raffles as many business owners and investors are seeking solutions to their financial situations amid the COVID-19 pandemic;
- Rising wave of acquisitive Chinese companies venturing beyond their national borders has created an uptick in outbound transactions;
- Asia-Pacific is expected to continue to dominate global IPO activity year-to-date in 2020 by volume.

Future Plans

- To expand our market by adding more Provincial Representatives;
- To enter into Strategic Partnerships and cooperation with international banks, venture capital firms, incubators, etc.;
- To invest in businesses that meet our investment criteria and guidelines;
- To strengthen our market liquidity and shareholder base.

Fiscal 2020 Financial Results Summary

The Company generated revenues of $8,866,672, which was derived from two major service segments, namely financial advisory service and licensing service (compared to $11,533,334 in fiscal 2019). The difference in revenue between fiscal 2019 and fiscal 2020 can be attributed to:

- the COVID-19 pandemic which caused travel restrictions and shutdowns that delayed and suspended the delivery of our advisory services (namely Re-structuring & Corporate Finance Advisory ("RCF"), IPO & Global Fund Raising Advisory ("IRS") and Fund, Family Office, Trust Advisory ("FOT")), and created difficulties for the Company to service clients in most of the major cities in which the Company operates including, among others, China, Hong Kong and Singapore;
- there were no FOT advisory service agreements entered into with clients so no fee income from FOT services during 2020 ($1,500,000 in 2019);
- suspension in licensing services with clients pursuant to force majeure clause in response to the COVID-19 outbreak since January 2020. The Company had agreed with its clients (the Regional Representatives) who were based in the PRC to suspend the contracted licensing services commencing in January 2020. The COVID-19 outbreak had a significant impact not only on the Company itself but also the Company's clients in PRC, as they had been hindered from performing their obligations under their service agreements due to the lockdown imposed by the local authorities and market downturn during and after the COVID-19 outbreak. Consequently, licensing services with clients was suspended until the clients can fully resume operations.

Administrative expenses for fiscal 2020 amounted to $1,565,443, compared to $782,682 in 2019. The difference between fiscal 2019 and fiscal 2020 was mainly due to:

- a non-cash item of share-based compensation of $297,610 pertaining to stock options granted to certain management and directors of the Company (2019: nil);
- a business development and marketing expenses amounting to $205,727 (2019: nil);
- increased professional fees, directors fee and staff costs arising from the RTO transaction and incurred after listing.

The comprehensive income for the year was $4,494,115 compared to $9,560,301 in 2019.

Excluding the listing expense related to the RTO in the amount of $6,052,280 (it comprised of a non-cash consideration of $5,479,920 recognised under IFRS 3 in accounting for the RTO), the Company made a comprehensive income of $10,546,395 in 2020 (comprising of operating profits of $5,627,051 and other comprehensive Income of $4,919,344). In 2019, the Company had a comprehensive income of $9,560,301.

Full details of the Company's 2020 financial results can be found in the Audited Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the years ended June 30, 2020, which are available at www.sedar.com.

About Raffles Financial Group Limited (CSE: RICH) (FSE: 4VO) (OTC: RAFFF)

Raffles Financial Pte. Ltd. (a wholly-owned subsidiary of Raffles Financial Group Limited) is an exempt corporate finance advisory firm, registered with the Monetary Authority of Singapore, which provides public listing advisory and arrangement services. Raffles Financial serves as advisor for family trusts, family offices and investment funds. Please visit www.rafflesfinancial.co for more information.

For more information, please contact:
Cathy Hume, Investor Relations
Phone: 416-868-1079 x 231
Email: cathy@chfir.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in Canadian securities laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the anticipated partnerships with financial institutions worldwide and the growth potential through Province Representatives. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67117


Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02

Raffles Announces 2020 Fiscal Year-End Financial Results

Vancouver, BC, Oct 29, 2020 - (ACN Newswire) - Raffles Financial Group Limited (CSE: RICH) (FSE: 4VO) (OTC: RAFFF) ("Raffles" or "the Company") today announces its financial results for the fiscal year ended June 30, 2020, highlighted by revenue of $8,866,672 and adjusted comprehensive income before other items and income tax expenses of $12,220,573. All amounts expressed are in Singapore dollars.

2020 Financial Highlights:

- Total Revenue of $8,866,672 (2019: $11,533,334)
- Adjusted comprehensive income before other items and income tax expenses3 of $12,220,573 (2019: $10,750,652)
- Cash Flow from operations of $7,044,654 (2019: $11,002,734)
- The Company generated cash inflow from financing activities of $20,296,000 (2019: cash outflow of $8,900,000) related to the completion of a private placement for gross proceeds of $20,296,000.

Comparative Summary of Key Financial Metrics for 2019 and 2020

2020 - 2019
Revenue $8,866,672 $11,533,334
Unrealized gain on investments $4,748,139 -
Operating expenses(*1) $1,565,443 $782,682
Listing expenses for RTO(*2) $6,052,280 -
Adjusted comprehensive income before other items and income tax expenses(*3) $12,220,573 $10,750,652
Net Income (Loss) ($425,229) $9,560,301

(*1) Operating expenses do not include interest, taxes, depreciation (including impairment of intangible assets) and amortization, and other non-recurring Items and non-cash accounting expenses.
(*2) Listing expense relates to the RTO in the amount of $6,052,280, which comprised of a non-cash acquisition consideration of $5,479,920 recognised under IFRS 3 in accounting for the reverse take over transaction ("RTO").
(*3) Adjusted comprehensive income before other items and income tax expenses equals income before other items and income tax expenses plus other comprehensive income includes Foreign currency translation and unrealized gain on investments.

Review of 2020

The Company's sole operating subsidiary, Raffles Financial Private Limited ("RFP"), first appeared in the second quarter of the calendar year 2020, marking the beginning of the Company tapping into the corporate finance advisory segment exclusively. From a financial standpoint, the Company was able to exceed its revenue and earning objectives for the year. From an operational standpoint, the Company disposed its old business and continued to make inroads into the Asia financial market through its services provided by RFP. The highly customisable service provided to its small to medium clients, coupled with its unique professional and low-cost service, are value-propositions that continue to resonate with and account for its adoption rate among industry players.

Outlook for 2021

- Significant opportunities for Raffles as many business owners and investors are seeking solutions to their financial situations amid the COVID-19 pandemic;
- Rising wave of acquisitive Chinese companies venturing beyond their national borders has created an uptick in outbound transactions;
- Asia-Pacific is expected to continue to dominate global IPO activity year-to-date in 2020 by volume.

Future Plans

- To expand our market by adding more Provincial Representatives;
- To enter into Strategic Partnerships and cooperation with international banks, venture capital firms, incubators, etc.;
- To invest in businesses that meet our investment criteria and guidelines;
- To strengthen our market liquidity and shareholder base.

Fiscal 2020 Financial Results Summary

The Company generated revenues of $8,866,672, which was derived from two major service segments, namely financial advisory service and licensing service (compared to $11,533,334 in fiscal 2019). The difference in revenue between fiscal 2019 and fiscal 2020 can be attributed to:

- the COVID-19 pandemic which caused travel restrictions and shutdowns that delayed and suspended the delivery of our advisory services (namely Re-structuring & Corporate Finance Advisory ("RCF"), IPO & Global Fund Raising Advisory ("IRS") and Fund, Family Office, Trust Advisory ("FOT")), and created difficulties for the Company to service clients in most of the major cities in which the Company operates including, among others, China, Hong Kong and Singapore;
- there were no FOT advisory service agreements entered into with clients so no fee income from FOT services during 2020 ($1,500,000 in 2019);
- suspension in licensing services with clients pursuant to force majeure clause in response to the COVID-19 outbreak since January 2020. The Company had agreed with its clients (the Regional Representatives) who were based in the PRC to suspend the contracted licensing services commencing in January 2020. The COVID-19 outbreak had a significant impact not only on the Company itself but also the Company's clients in PRC, as they had been hindered from performing their obligations under their service agreements due to the lockdown imposed by the local authorities and market downturn during and after the COVID-19 outbreak. Consequently, licensing services with clients was suspended until the clients can fully resume operations.

Administrative expenses for fiscal 2020 amounted to $1,565,443, compared to $782,682 in 2019. The difference between fiscal 2019 and fiscal 2020 was mainly due to:

- a non-cash item of share-based compensation of $297,610 pertaining to stock options granted to certain management and directors of the Company (2019: nil);
- a business development and marketing expenses amounting to $205,727 (2019: nil);
- increased professional fees, directors fee and staff costs arising from the RTO transaction and incurred after listing.

The comprehensive income for the year was $4,494,115 compared to $9,560,301 in 2019.

Excluding the listing expense related to the RTO in the amount of $6,052,280 (it comprised of a non-cash consideration of $5,479,920 recognised under IFRS 3 in accounting for the RTO), the Company made a comprehensive income of $10,546,395 in 2020 (comprising of operating profits of $5,627,051 and other comprehensive Income of $4,919,344). In 2019, the Company had a comprehensive income of $9,560,301.

Full details of the Company's 2020 financial results can be found in the Audited Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the years ended June 30, 2020, which are available at www.sedar.com.

About Raffles Financial Group Limited (CSE: RICH) (FSE: 4VO) (OTC: RAFFF)

Raffles Financial Pte. Ltd. (a wholly-owned subsidiary of Raffles Financial Group Limited) is an exempt corporate finance advisory firm, registered with the Monetary Authority of Singapore, which provides public listing advisory and arrangement services. Raffles Financial serves as advisor for family trusts, family offices and investment funds. Please visit www.rafflesfinancial.co for more information.

For more information, please contact:
Cathy Hume, Investor Relations
Phone: 416-868-1079 x 231
Email: cathy@chfir.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute "forward-looking statements" or "forward-looking information" (collectively "forward-looking information") as those terms are used in Canadian securities laws. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "estimated", "anticipates" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company's current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, the anticipated partnerships with financial institutions worldwide and the growth potential through Province Representatives. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67117

Copyright 2020 ACN Newswire. All rights reserved. www.acnnewswire.com

source http://www.acnnewswire.com/press-release/english/62360/

CITIC Telecom CPC X OpenRice Cooking up Technological Transformation with a Food Tech Ecosystem, To Always Deliver More Than Expected

HONG KONG, Oct 29, 2020 - (JCN Newswire) - CITIC Telecom International CPC Limited ("CITIC Telecom CPC"), a wholly owned subsidiary of CITIC Telecom International Holdings Limited (SEHK:1883) together with the most popular and award-winning dinning guide OpenRice today celebrate their business collaboration. Using innovative technology to build a reliable dining experience and one-stop merchant platform, in reaching new heights for Asia FoodTech Ecosystems, OpenRice has won three category awards at the "IDC Digital Transformation Awards" - Omni-experience Innovator - Hong Kong, and DX CEO - Hong Kong and Regional.

CITIC Telecom CPC Supports OpenRice's Digital Transformation Journey
OpenRice has been going through a digital transformation journey in recent years, where they have gone from an online dining guide to a FoodTech Ecosystem. With its success in digital transformation, OpenRice has won three IDC Digital Transformation Awards - for Omni-experience Innovator - Hong Kong, and DX CEO - Hong Kong and Regional.

The IDC Digital Transformation Awards recognise the achievements of organisations that distinguished themselves with notable and measurable success in the execution of their organisation's digital transformation (DX) initiatives across the seven DX masteries and who make significant efforts to transform or disrupt the market.

During the digital shift, OpenRice redeveloped its Table Booking System into a native app and website, connecting consumers, restaurants and partners in the F&B and non-F&B sectors. The new initiative included the transformation of a table booking system into one-stop merchant platform "OpenRice Biz" to support restaurants' dining business journey, improve the availability of market insight solutions for merchants, as well as provide agile and digital business operations. Enabling technologies, including big data analytics and AI, were adopted to empower the initiative.

"With a majority of food and beverage merchants lacking the technology know-how and budget, OpenRice as a platform has taken the leading position to innovate and enhance services for restaurants. Thus, we introduced the OpenRice Biz Platform, where restaurant merchants can choose from a suite of dining solutions or have customised plans tailored specifically to better fit their needs. This was how our journey of digital transformation began," said Joe Yau, CEO at OpenRice. "We see digitalization as a part of the company's daily routine; growing with it and evolving with it has become second nature amidst the growing digital economy."

Delivering the Most Important Package in the Dining Journey: TRUST
As OpenRice continued to expand its platform business with increasing traffic, transactions and data volume, a more reliable security solution was needed. This is where CITIC Telecom CPC came in to assist OpenRice with their security and network system.

"With increasing cyber-attacks and phishing emails, as well as a rising amount of data usage due to the expansion of our service offerings, we needed to enhance our security level and data transmission," said Yau. "With CITIC Telecom CPC's TrustCSI(TM) UTM and Email Protection services, plus its TrueCONNECT(TM) MPLS connectivity service in place, OpenRice now enjoys reliable data flow and better data protection to help safeguard our business."

"CITIC Telecom CPC always strives to serve our customers with strong support for their business digital transformation, and we are glad that our TrustCSI(TM) information security services and TrueCONNECT(TM) private network solutions have helped to support OpenRice's secure dining platform," said Mr. Taylor Lam, Senior Vice President of Product Development & Management at CITIC Telecom CPC. "The OpenRice FoodTech ecosystem redefines users' total dining experience and services merchants' business operations, as well as sales and marketing strategies. Appreciating its success, CITIC Telecom CPC nominated OpenRice for the IDC Digital Transformation Awards and we feel honoured that it has won awards in three categories."

CITIC Telecom CPC's Security Solutions Revamped to Support its DX Strategy
Given that DX is no longer an option but a must-have process for any type of business, CITIC Telecom CPC's innovative solutions and experienced experts have put it in a leading position to help enterprises on their DX journey. CITIC Telecom CPC's new DX strategy will ensure that it is a strong ICT-enabler to support the digital transformation of various industries. In fact, with 5G+ bringing DX into a new era, CITIC Telcom CPC's solutions will help enabling enterprises to better leverage technologies. For example, 5G+ will allow Artificial Intelligence (AI), IoT, and even autonomous driving to reach new heights, while CITIC Telecom CPC's solutions suite assures enterprises by helping them to leverage these technologies in a secure and effective manner to achieve their DX goals.

"Innovation Never Stops. Our Digitalization strategy is simple, it not only about machines and technologies, but also about talent and customer experience. We are putting people at the centre of the DX Journey, and truly believe it is people's skills and their ability to learn, adapt, change and innovate that makes any technology implementation successful," said Daniel Kwong, Chief Information and Innovation Officer from CITIC Telecom CPC.

"Furthermore, the way we work is primarily about keeping customers at the centre and we plan everything around them to ensure we are aligned to both their strategy and their business goals. Recognising that digital transformation is no longer a choice but rather an inescapable and exponentially growing process, enterprises are quickly adopting and leveraging new technologies to embrace the digital era. CITIC Telecom CPC is committed to helping clients navigate their digital transformation journeys, through the provision of a wide range of innovative solutions created from powerful new disruptive technologies," added Kwong.

Since the next generation of digital business will be run by underlying data, there is a crucial security element that now needs to be considered - cybersecurity and a company's networks and systems will need to be combined. Thus, security will no longer just be another system requirement, it will be one of the key enablers of digital transformation.

"As one of the key components of our DX strategy, we are revamping our TrustCSI(TM) portfolio to fulfill customer demand during their digital transformation journey," said Lam. "With new additional services and technology enhancements, our security service portfolio now consists of four key service scopes - Device Management Service, Threat Detection and Response Service, Behaviour Analysis Service, and Professional Service. Customers can now enjoy comprehensive security solution offerings, and select the most suitable services to help them digitally transform their operations."

Embedded with the latest powerful analytics-driven SIEM and superior Dashboards capability, TrustCSI(TM) 2.0 can empower customers and teams with data insights in real-time, making it fast and easy for everyone to visualise and deliver numerous capabilities at-scale, as well as to address modern threats demand analytics-driven security and continuous monitoring.

The key enhancements of this revamp include the launch of the Incident Response (IR) and Security Orchestration, Automation and Response (SOAR) functions under the Threat Detection and Response Service scope, and a consultation service for China Cybersecurity Law MLPS 2.0 compliance under the Professional Services scope.

Threat Detection and Response Service
With the new generation of Security Information and Event Management (SIEM) technology, CITIC Telecom CPC brings a whole new experience to its customers. The enhanced SIEM platform can support modern cloud applications and type of workload and provide a flexible deployment model including on-premises, cloud, and hybrid models. An advanced monthly report and customised monitoring dashboard will be available for customers, giving them a clear picture on their security aspects.

What's more, the IR and SOAR services are added to help customers identify potential threats from different devices without human intervention. Remediation actions and suggested measures will be provided to resolve an issue automatically in the future.

The new IR feature is able to:
- Shorten investigation cycles - prioritise, confirm, and act on higher priority threats
- Use an Investigation Workbench to investigate notable events that may represent a threat
- Leverage integration with existing capabilities - by collaborating and tracking an investigation
- Quickly launch a response to critical incidents

The new SOAR service can:
- Automate repetitive tasks so that customers can allocate their resources to higher value tasks
- Automate security alerts allowing customers to keep everything under control, instead of dealing with overwhelming alerts
- Orchestrate workflows and responses across all products so that each device can actively participate in the defence strategy
- Save time and resources by resolving issues and making current tools work better

Professional Services
People are the key to any enterprises DX journey, and CITIC Telecom CPC can help by providing the resources to help client personnel learn and understand fast changing policy and compliance changes. This service includes being able to help companies enter the Chinese market with China Cybersecurity Law MLPS 2.0 compliance. For enterprises expanding or already operating inside China, it is imperative their digital transformation be in compliance with the law. This service includes classification, filing, implementation, evaluation, and auditing, and is easy, reliable, and professionally administered to ensure an enterprise operates a robust, fully compliant MLPS 2.0 infrastructure. Other Professional Services offered by CITIC Telecom CPC include vulnerability assessment, penetration testing, and security device migration.

Together with the existing yet powerful Device Management Service, which provides round-the-clock comprehensive and reliable infrastructure management services to handle the crucial burden of regular diligent device and software management, and the TrustCSI(TM) Behavior Analysis Service which brings a new approach to enterprise cyber defense, CITIC Telcom CPC's solutions provide a secure journey for companies that are going through the digital transformation process.

About OpenRice
Established in 1999, OpenRice is currently the most popular food dining guide in Hong Kong. The database contains the most complete and updated restaurant information, with credible restaurant reviews written by real locals. As the most comprehensive F&B platform in Hong Kong, OpenRice is devoted to the research and development of FoodTech to create a sustainable one-stop shop of solutions in the eco-system; including Restaurant Management System (RMS), Recruitment, POS & integrated payment, Table booking & dine-in solutions, Scan to Order, Vouchers, TakeAway , Analytics, and beyond!

Based in Hong Kong, OpenRice has also actively expanded to other Asian regions in recent years, including Macau, Taiwan, Japan, Thailand, Singapore, Malaysia, and China.

About CITIC Telecom CPC
We are CITIC Telecom International CPC Limited ("CITIC Telecom CPC"), a wholly owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT(TM) private network solutions, TrustCSI(TM) information security solutions, DataHOUSE(TM) cloud data center solutions, and SmartCLOUD(TM) cloud computing solutions.

As a leading Global Local ICT Solutions Partner with worldwide footprint across East to West and native presence, we truly live our motto, "Innovation Never Stops." Being a preferred Digital Society Enabler, we lead our key markets at the forefront of pioneering ICT development, embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies to transform technical potential into real-world value for our customers, helping them achieve higher productivity, agility, cost-efficiency, and ultimately, Digital Globalization.

As one of the first managed service providers in Hong Kong to achieve ISO 9001, 14001, 20000, 27001, and 27017 ICT-related certifications, CITIC Telecom CPC delivers on our superior quality commitment through a broad global self-managed infrastructure encompassing some of the highest growth markets in Asia, Europe and America, with over 140 points of presence, 18 Cloud service centers, 30+ data centers, and two dedicated 24x7 Security Operations Centers.

For more information please visit www.citictel-cpc.com

Media Contacts:

Rowena Leung
CITIC Telecom International CPC Limited
(852) 2170 7536
Email: rowena.leung@citictel-cpc.com




Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com Via JCN Newswire https://ift.tt/2pbRN02